The Michael J. Fox Foundation Receives FDA Approval and Advances to Market
On May 21, 2020, the U.S. Food and Drug Administration approved Kynmobi from Sunovion Pharmaceuticals Inc. This new therapy — which treats "off" time, when PD symptoms are not well controlled with oral medication — marks the second regulatory approval of a Parkinson's treatment funded by the Foundation.
NJHA Charts Rise and Fall of COVID Hospitalizations; Peak Occurred April 14
NJHA reported its first COVID-19 case on March 4. The rapid rise of the virus in New Jersey culminated on April 14, when the state's hospitals experienced peaks.
Dr Nalini Rajamannan Reports to Northwestern University, Chicago IL VP: COVID-19 Non-Compliance in Clinical Trials
Dr. Nalini Rajamannan is a heart valve expert in the field of cardiovascular medicine.
New Study Published in the New England Journal of Medicine Shows COVID-19 Causes Blood Vessel Damage
New England Journal of Medicine shows that the respiratory virus SARS-CoV-2, which causes COVID-19, causes severe damage to blood vessels, leading to widespread thrombosis, or blood clotting, in the lung.
FDA Provides Promised Transparency for Antibody Tests
FDA notes: Antibody tests on this new removal list include those voluntarily withdrawn from the notification list by the test's commercial manufacturer and those for which there is not a pending Emergency Use Authorization (EUA) request or issued EUA.